Impact of supplementing Limosilactobacillus fermentum MN–LF23 on the eradication of Helicobacter pylori with 14–day standard quadruple therapy: a randomized, double–blind, placebo–controlled trial
Abstract Background The effect of probiotics on Helicobacter pylori (Hp) infection demonstrates considerable heterogeneity. This study aims to elucidate the role of Limosilactobacillus fermentum MN–LF23 (MN–LF23) in Hp–infected populations. Methods A total of 94 adult patients with confirmed Hp infe...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Nutrition Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12937-025-01124-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849344183959027712 |
|---|---|
| author | Yuyang Zhao Xiaokang Niu Yong Zhang Liang Zhao Liwei Zhang Jingjing He Qi Zhang Yuejian Mao Fuqing Wang Xiaohui Zhao Ran Wang |
| author_facet | Yuyang Zhao Xiaokang Niu Yong Zhang Liang Zhao Liwei Zhang Jingjing He Qi Zhang Yuejian Mao Fuqing Wang Xiaohui Zhao Ran Wang |
| author_sort | Yuyang Zhao |
| collection | DOAJ |
| description | Abstract Background The effect of probiotics on Helicobacter pylori (Hp) infection demonstrates considerable heterogeneity. This study aims to elucidate the role of Limosilactobacillus fermentum MN–LF23 (MN–LF23) in Hp–infected populations. Methods A total of 94 adult patients with confirmed Hp infection were enrolled in this study and randomly allocated to the placebo or MN–LF23 group. Patients initially received either placebo or probiotics along with standard quadruple therapy for 2 weeks, followed by continued administration of either placebo or probiotics for an additional 4 weeks. The eradication of Hp, serum levels of inflammatory factors, and alterations in gastrointestinal symptoms were assessed at weeks 0, 2, and 6, while fecal samples were collected for metagenomic sequencing. Results The results showed no significant difference (P = 1) in the eradication rate between the placebo group (85.11%) and the probiotic group (82.98%). Following treatment, the incidence of constipation, dyspepsia, and Gastrointestinal Symptom Rating Scale (GSRS) scores in the probiotic group were markedly lower (P < 0.05) compared to those observed in the placebo group. Throughout the treatment process, there were no significant differences in TNF–α and IL–1β levels between the two groups. Compared to the placebo group, the probiotic group exhibited a significant increase in beneficial bacteria such as Limosilactobacillus fermentum, Lactiplantibacillus plantarum, Bifidobacterium longum, Coprococcus caltus, and Clostridium butyricum. Conclusion MN–LF23 supplementation did not improve the eradication rate of standard quadruple therapy. However, it significantly reduced the overall GSRS score, improved digestive and constipation symptoms, and promoted the proliferation of beneficial bacteria in the intestine. |
| format | Article |
| id | doaj-art-192843d145e74b0289a16c206885a7f6 |
| institution | Kabale University |
| issn | 1475-2891 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Nutrition Journal |
| spelling | doaj-art-192843d145e74b0289a16c206885a7f62025-08-20T03:42:44ZengBMCNutrition Journal1475-28912025-07-0124111210.1186/s12937-025-01124-6Impact of supplementing Limosilactobacillus fermentum MN–LF23 on the eradication of Helicobacter pylori with 14–day standard quadruple therapy: a randomized, double–blind, placebo–controlled trialYuyang Zhao0Xiaokang Niu1Yong Zhang2Liang Zhao3Liwei Zhang4Jingjing He5Qi Zhang6Yuejian Mao7Fuqing Wang8Xiaohui Zhao9Ran Wang10Department of Food Science and Nutritional Engineering, Key Laboratory of Functional Dairy, Co–constructed by Ministry of Education and Beijing Government, China Agricultural UniversityDepartment of Nutrition and Health, Key Laboratory of Functional Dairy, Co–Constructed by Ministry of Education and Beijing Government, China Agricultural UniversityDepartment of Nutrition, The First Medical Center of Chinese PLA General HospitalDepartment of Food Science and Nutritional Engineering, Key Laboratory of Functional Dairy, Co–constructed by Ministry of Education and Beijing Government, China Agricultural UniversityDepartment of Nutrition and Health, Key Laboratory of Functional Dairy, Co–Constructed by Ministry of Education and Beijing Government, China Agricultural UniversityDepartment of Nutrition and Health, Key Laboratory of Functional Dairy, Co–Constructed by Ministry of Education and Beijing Government, China Agricultural UniversityDepartment of Nutrition and Health, Key Laboratory of Functional Dairy, Co–Constructed by Ministry of Education and Beijing Government, China Agricultural UniversityMengniu Institute of Nutrition Science, Global R&D Innovation Center, Inner Mongolia Mengniu Dairy (Group) Co., LtdTibet Tianhong Science and Technology Co., LtdMengniu Institute of Nutrition Science, Global R&D Innovation Center, Inner Mongolia Mengniu Dairy (Group) Co., LtdDepartment of Nutrition and Health, Key Laboratory of Functional Dairy, Co–Constructed by Ministry of Education and Beijing Government, China Agricultural UniversityAbstract Background The effect of probiotics on Helicobacter pylori (Hp) infection demonstrates considerable heterogeneity. This study aims to elucidate the role of Limosilactobacillus fermentum MN–LF23 (MN–LF23) in Hp–infected populations. Methods A total of 94 adult patients with confirmed Hp infection were enrolled in this study and randomly allocated to the placebo or MN–LF23 group. Patients initially received either placebo or probiotics along with standard quadruple therapy for 2 weeks, followed by continued administration of either placebo or probiotics for an additional 4 weeks. The eradication of Hp, serum levels of inflammatory factors, and alterations in gastrointestinal symptoms were assessed at weeks 0, 2, and 6, while fecal samples were collected for metagenomic sequencing. Results The results showed no significant difference (P = 1) in the eradication rate between the placebo group (85.11%) and the probiotic group (82.98%). Following treatment, the incidence of constipation, dyspepsia, and Gastrointestinal Symptom Rating Scale (GSRS) scores in the probiotic group were markedly lower (P < 0.05) compared to those observed in the placebo group. Throughout the treatment process, there were no significant differences in TNF–α and IL–1β levels between the two groups. Compared to the placebo group, the probiotic group exhibited a significant increase in beneficial bacteria such as Limosilactobacillus fermentum, Lactiplantibacillus plantarum, Bifidobacterium longum, Coprococcus caltus, and Clostridium butyricum. Conclusion MN–LF23 supplementation did not improve the eradication rate of standard quadruple therapy. However, it significantly reduced the overall GSRS score, improved digestive and constipation symptoms, and promoted the proliferation of beneficial bacteria in the intestine.https://doi.org/10.1186/s12937-025-01124-6Helicobacter pyloriLimosilactobacillus fermentumStandard quadruple therapyGut microbiotaMetagenomic sequencing |
| spellingShingle | Yuyang Zhao Xiaokang Niu Yong Zhang Liang Zhao Liwei Zhang Jingjing He Qi Zhang Yuejian Mao Fuqing Wang Xiaohui Zhao Ran Wang Impact of supplementing Limosilactobacillus fermentum MN–LF23 on the eradication of Helicobacter pylori with 14–day standard quadruple therapy: a randomized, double–blind, placebo–controlled trial Nutrition Journal Helicobacter pylori Limosilactobacillus fermentum Standard quadruple therapy Gut microbiota Metagenomic sequencing |
| title | Impact of supplementing Limosilactobacillus fermentum MN–LF23 on the eradication of Helicobacter pylori with 14–day standard quadruple therapy: a randomized, double–blind, placebo–controlled trial |
| title_full | Impact of supplementing Limosilactobacillus fermentum MN–LF23 on the eradication of Helicobacter pylori with 14–day standard quadruple therapy: a randomized, double–blind, placebo–controlled trial |
| title_fullStr | Impact of supplementing Limosilactobacillus fermentum MN–LF23 on the eradication of Helicobacter pylori with 14–day standard quadruple therapy: a randomized, double–blind, placebo–controlled trial |
| title_full_unstemmed | Impact of supplementing Limosilactobacillus fermentum MN–LF23 on the eradication of Helicobacter pylori with 14–day standard quadruple therapy: a randomized, double–blind, placebo–controlled trial |
| title_short | Impact of supplementing Limosilactobacillus fermentum MN–LF23 on the eradication of Helicobacter pylori with 14–day standard quadruple therapy: a randomized, double–blind, placebo–controlled trial |
| title_sort | impact of supplementing limosilactobacillus fermentum mn lf23 on the eradication of helicobacter pylori with 14 day standard quadruple therapy a randomized double blind placebo controlled trial |
| topic | Helicobacter pylori Limosilactobacillus fermentum Standard quadruple therapy Gut microbiota Metagenomic sequencing |
| url | https://doi.org/10.1186/s12937-025-01124-6 |
| work_keys_str_mv | AT yuyangzhao impactofsupplementinglimosilactobacillusfermentummnlf23ontheeradicationofhelicobacterpyloriwith14daystandardquadrupletherapyarandomizeddoubleblindplacebocontrolledtrial AT xiaokangniu impactofsupplementinglimosilactobacillusfermentummnlf23ontheeradicationofhelicobacterpyloriwith14daystandardquadrupletherapyarandomizeddoubleblindplacebocontrolledtrial AT yongzhang impactofsupplementinglimosilactobacillusfermentummnlf23ontheeradicationofhelicobacterpyloriwith14daystandardquadrupletherapyarandomizeddoubleblindplacebocontrolledtrial AT liangzhao impactofsupplementinglimosilactobacillusfermentummnlf23ontheeradicationofhelicobacterpyloriwith14daystandardquadrupletherapyarandomizeddoubleblindplacebocontrolledtrial AT liweizhang impactofsupplementinglimosilactobacillusfermentummnlf23ontheeradicationofhelicobacterpyloriwith14daystandardquadrupletherapyarandomizeddoubleblindplacebocontrolledtrial AT jingjinghe impactofsupplementinglimosilactobacillusfermentummnlf23ontheeradicationofhelicobacterpyloriwith14daystandardquadrupletherapyarandomizeddoubleblindplacebocontrolledtrial AT qizhang impactofsupplementinglimosilactobacillusfermentummnlf23ontheeradicationofhelicobacterpyloriwith14daystandardquadrupletherapyarandomizeddoubleblindplacebocontrolledtrial AT yuejianmao impactofsupplementinglimosilactobacillusfermentummnlf23ontheeradicationofhelicobacterpyloriwith14daystandardquadrupletherapyarandomizeddoubleblindplacebocontrolledtrial AT fuqingwang impactofsupplementinglimosilactobacillusfermentummnlf23ontheeradicationofhelicobacterpyloriwith14daystandardquadrupletherapyarandomizeddoubleblindplacebocontrolledtrial AT xiaohuizhao impactofsupplementinglimosilactobacillusfermentummnlf23ontheeradicationofhelicobacterpyloriwith14daystandardquadrupletherapyarandomizeddoubleblindplacebocontrolledtrial AT ranwang impactofsupplementinglimosilactobacillusfermentummnlf23ontheeradicationofhelicobacterpyloriwith14daystandardquadrupletherapyarandomizeddoubleblindplacebocontrolledtrial |